The pharmacology of Parkinson's disease therapy: An update

Annual Review of Pharmacology and Toxicology

Volumn 33, Issue , 1993, Pages 467-495

  Kopin, Irwin J ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Bromocriptine; Deprenyl; Dopamine; Dopamine receptors; Levodopa

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOMPERIDONE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR AFFECTING AGENT; LEVODOPA; LISURIDE; N (6 OXO 1H PYRID 2 YL) N',N' DIPROPYLFORMAMIDINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITECAPONE; PERGOLIDE; PROPYLNORAPOMORPHINE; QUINPIROLE; RECEPTOR SUBTYPE; SELEGILINE; TOLCAPONE;

DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0027401022     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pa.33.040193.002343     Document Type: Review

References (129)

1. Carlsson, A., Lindquist, M., Magnusson, T., Waldeck, B. 1958. On the presence of 3 hydroxytyramine in brain. Science 127:471-72
2. Enringer, H., Hornykiewicz, O. 1960. Verteilung von Noradrenalin und Dopamin (3-hydroxytramin) in Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38:1236-39
3. Corbin, K. B. 1949. Trihexyphenyl: evaluation of a new agent in the treatment of Parkinson's disease. J. Am. Med. Assoc. 141:373-81
4. Dorshay, L. J., Constable, K. 1949. Active therapy for Parkinsonism. J. Am. Med. Assoc. 140:1317
5. Schwab, R. S., England, A. C., Poskahzer, D. C., Young, R. R. 1969. Amantadine in the treatment of Parkinson's disease. J. Am. Med. Assoc. 208:1168-70
6. Budnitz, J. 1948. Use of benadryl in Parkinson's disease. N. Engl. J. Med. 238:874
7. Solomon, P., Mitchell, R. S., Prinzmetal, M. 1937. The use of benzedrine sulfate in post-encephalitic Parkinson's disease. J. Am. Med. Assoc. 108:1765-70
8. Schwab, R. S., Amador, L, V., Lettvin, J. Y. 1951. Apomorphine Parkinson's disease. Trans. Am. Neurol. Assoc. 76:251
9. Cotzias, G. C., Van Woert, M. H., Schiffer, L. M. 1967. Aromatic amino acids and modification of Parkinsonism. N. Engl. J. Med. 276:374-78
10. Cotzias, G. C., Papavasiliou, P. S., Gellene, R. 1969. Modification of parkinsonism - chronic treatment with L-dopa. N. Engl. J. Med. 280:337-45
11. Papavasiliou, P. S., Cotzias, G. C., Duby, S. E., Steck, A. J., Fehling, C., Bell, M. A. 1972. Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. N. Engl. J. Med. 286:8-14
12. Pletscher, A. 1973. Effect of inhibitors of extracerebral decarboxylase on levodopa metabolism. Adv. Neurol. 3:49-58
13. Finder, R. M., Brogden, R. N., Sawyer, P. R., Speight, T. M., Avery, G. S. 1976. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 11: 329-77
14. Báckstróm, R., Honkanen, E., Pippuri, A., Kairisalo, P., Pystynen, J., et al. 1989. Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J. Med. Chem. 32: 841-46
15. Linden, I. B., Nissinen, E., Etemadzadeh, E., Kaakkola, S., Männistö, P., Pohto, P. 1988. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J. Pharmacol. Exp. Ther. 247:289-93
16. Männistö, P. T., Kaakkola, S., Nissinen, E., Linden, I. B., Pohto, P. 1988. Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci. 43:1465-71
17. Nissinen, E., Linden, I. B., Schultz, E., Kaakkola, S., Männistö, P. T., Pohto, P. 1988. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur. J. Pharmacol. 153:263-69
18. Männistö, P. T., Tuomainen, P. 1991. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn-Schmiedebergs Arch. Pharmakol. 344(4):412-41
19. Cedarbaum, J. M., Leger, G., Reches, A., Guttman, M. 1990. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys. Clin. Neuropharmacol. 13:544-52
20. Cedarbaum, J. M., Leger, G., Guttman, M. 1991. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin. Neuropharmacol. 14:330-42
21. Schultz, E., Tarpila, S., Bäckström, A. C., Gordin, A., Nissinen, E., Pohto, P. 1991. Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone. Eur. J. Clin. Pharmacol. 40:577-80
22. Kaakkola, S., Gordon, A., Jarvinen, M., Wikberg, T., Schultz, E., et al. 1990. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin. Neuropharmacol. 13(5):436-37
23. Zurcher, G., Colzi, A., Da Prada, M. 1990. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J. Neural Transm. 32:375-80 (Suppl.)
24. Maj, J., Rogo, Z., Skuza, G., Sowinska, H., Superata, J. 1990. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J. Neural. Transm. Park. Dis. Dement. Sect. 2(2):101-26
25. Brannan, T., Martinez-Tica, J., Yahr, M. 1992. Catechol-O-methyl transferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats. Neurology 42:683-85
26. Acquas, E., Carboni, E., de Ree, R. H., Da Prada, M., Di Chiara, G. 1992. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J. Neurochem. 59:326-30
27. Tedroff, J., Hartvig, P., Bjurling, P., Andersson, Y., Antoni, G., Langstrom, B. 1991. Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J. Neural Transm. Gen. Sect. 85:11-17
28. Waldmeler, P. C., Baumann, P. A., Feldtrauer, J. J., Hauser, K., Bittiger, H., et al. 1990. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn-Schmiedebergs Arch. Pharmakol. 342(3):305-11
29. Waldmeier, P. C., De Herdt, P., Maitre, L. 1990. Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat. J. Neural Transm. 32:381-86 (Suppl.)
30. Bleck, P. R., Nilsson, E., Antonin, K. H. 1990. Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects. J. Neural Transm. 32:387-91 (Suppl.)
31. Comi, G., Miletich, R., Kopin, I., Bankiewicz, K., Plunkett, R., et al. 1990. Metabolism and PET imaging of 6-[F-18]Fluoro-L-Dopa5AM after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Neurology 40:270
32. 18F]-6-Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology 42: 199-203
33. Kebablan, J. W., Calne, D. B. 1979. Multiple receptors for dopamine. Nature 277:93-96
34. Young, A. B., Penney, J. B. 1989. Receptors in the basal ganglia. In Drugs for the Treatment of Parkinson's Disease, ed. D. B. Calne, pp. 149-63. Berlin: Springer-Verlag
35. Parent, A. 1990. Extrinsic connections of the basal ganglia. Trends Neurosci. 13:254-58
36. Alexander, G. E., Crutcher, M. D. 1990. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:266-27
37. Graybiel, A. M. 1990. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:244-53
38. Gerfen, C. R. 1991. The neostriatal-mosaic: multiple levels of compartmental organization. Trends Neurosci. 14: 133-39
39. Gerfen, C. R. 1992. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 15:285-320
40. Yamamoto, B. K., Davy, S. 1992. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 58:1736-42
41. Mansour, A., Meador-Woodruff, J. H., Zhou, Q., Civelli, O., Akil, H., Watson, S. J. 1992. A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience 46:959-71
42. Harrison, M. B., Wiley, R. G., Wooten, G. F. 1990. Selective localization of striatal D1 receptors to striatonigral neurons. Brain Res. 528: 317-22
43. Thibaut, F., Hirsch, E. C., Raisman, R., Javoy-Agid, F., Agid, Y. 1990. Microtopography of D1 dopaminergic binding sites in the human substantia nigra: an autoradiographic study. Neuroscience 37(2):387-98
44. LaHoste, G. J., Marshall, J. F. 1990. Nigral D1 and striatal D2 receptors mediate behavioral effects of dopamine agonists. Behav. Brain Res. 28:233-42
45. Carlson, J. H., Bergstrom, D. A., Walters, J. R. 1986. Neurophysiological evidence that D1 dopamine receptor blockade attenuates postsynaptic but not autoreceptor-mediated effects of dopamine agonists. Eur. J. Pharmacol. 23:237-51
46. Walters, J. R., Bergstrom, D. A., Carlson, J. H., Weick, B. G., Pan, H. S. 1987. Stimulation of D-1 and D-2 dopamine receptors: synergistic effects on single unit activity in basal ganglia output nuclei. In Neurophysiology of Dopaminergic Systems: Current Status and Clinical Perspectives, ed. L. A. Chlodo, A. S. Freeman, pp. 299-316. Detroit: Lakeshore
47. Rouillard, C., Bedard, P. J., DiPaolo, T. 1990. Effects of chronic treatment of MPTP monkeys with bromocryptine alone or in combination with SKF38393. Eur. J. Pharmacol. 28: 209-15
48. Gomez-Mancilia, B., Boucher, R., Bedard, P. J. 1992. Effect of LY171 555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism. Mov. Disord. 7:43-47
49. 2 dopamine receptor mRNAs in rat brain. Neuropsychopharmacology 5:231-42
50. Stoof, J. C., Kebabian, J. W. 1981. Opposing roles for the D-1 and D-2 dopamine receptors in efflux of cAMP from rat neostriatum. Nature 294:366-68
51. +) ATPase activity in neostriatal neurons through D1 and D2 dopamine receptor synergism. Nature 347: 386-88
52. Seeman, P., Niznik, H. B., Guan, H. C., Booth, G., Ulpian, C. 1989. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc. Natl. Acad. Sci. USA 86:10156-60
53. Lieberman, A. N., Goldstein, M. 1985. Bromocriptine in Parkinson's disease. Pharmacol. Rev. 37:217-27
54. Markstein, R. 1981. Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions. J. Neural Transm. 51:39-59
55. Schran, H. F., Bhuta, S. I., Schwarz, H. J. 1980. The pharmacokinetics of bromocriptine in man. In Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects, ed. M. Goldstein, pp. 125-39. New York: Ravevi
56. Goldstein, M., Lieberman, A., Meller, E. 1985. A possible molecular mechanism forthe antiparkinsonian action of bromocriptine in combination with levodopa. Trends Phartnacol. Sci. 6: 436-37
57. LeWitt, P. A. 1984. Clinical and pharmacological aspects of the antiparkisonian ergolene lisuride. In Recent Developments in Parkinson's Disease, ed. S. Fahn, C. D. Marsden, P. Jenner, P. Teychenne, pp. 347-54. New York: Raven
58. Fuller, R. W., Clemens, J. A., Pergolide. 1991. A dopamine agonist at both D1 and D2 receptors. Life Sci. 49:925-30
59. Stoessl, A. J., Mak, E., Calne, D. B. 1985. (+)-4-propyl-9-hydroxynapthoxazine (PHNO), a new dopaminomimetic in treatment of parkinsonism. Lancet 2:1330-31
60. Rupniak, N. M. J., Tyc, S. J., Jennings, C. A., Loper, A. E., Bondi, J. V., et al. 1988. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology 39:329-35
61. Cedarbaum, J. M., Clark, M., Toy, L. H., Green-Parsons, A. 1990. Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation. Mov. Disord. 5:298-303
62. Alexander, G. M., Brainard, D. L., Gordon, S. W., Hichens, M., Grothusen, J. R., Schwartzman, R. J. 1991. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates. Brain Res. 547: 181-89
63. Bunzow, J. R., Van Tol, H. H., Grandy, D. K., Albert, P., Salon, J., et al. 1988. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336:783-87
64. 1 dopamine receptor. Nature 347:72-76
65. 1 dopamine receptors. Nature 347:76-80
66. 1 receptor encoded by an intronless gene on chromosome 5. Nature 347:80-83
67. Monsma, F. J. Jr., Mahan, L. C., McVittie, L. D., Gerfen, C. R., Sibley, D. R. 1990. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. USA 87:6723-27
68. 3) as a target for neuroleptics. Nature 347:146-51
69. Bouthenet, M. L., Souil, E., Martres, M. P., Sokoloff, P., Giros, B., Schwartz, J. C. 1991. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 564:203-19
70. Snyder, L. A., Roberts, J. L., Sealfon, S. C. 1991. Alternative transcripts of the rat and human dopamine D3 receptor. Biochem. Biophys. Res. Commun. 80:1031-35
71. 3 dopamine receptor produced through various patterns of alternative splicing. Biochem. Biophys. Res. Commun. 176:1584-92
72. 4 receptor with high affinity forthe antipsychotic clozapine. Nature 350:610-14
73. O'Malley, K. L., Harmon, S., Tang, L., Todd, R. D. 1992. The rat dopamine D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol. 4:137-46
74. 4 receptor variants in the human population. Nature 358:149-52
75. 1. Nature 350:614-19
76. 5 receptor pseudogenes. Gene 109:211-18
77. 5 pseudogene. Biochem. Biophys. Res. Commun. 181: 16-21
78. Michaels, M., Hendricks, R., Heykants, J. 1981. On the pharmacokinetics of domperidone in animals and men. II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. Eur. J. Drug Metab. Pharmacokinet. 6:47-54
79. Costall, B., Fortune, D. H., Naylor, R. J. 1978. Differential activities of some benzamide derivatives on peripheral and intracerebral administration. J. Pharm. Pharmacol. 30:726-98
80. Laduron, P. M., Leysen, J. E. 1979. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem. Pharmacol. 28:2161-65
81. Broaden, R. N., Carmine, A. A., Heel, R. C., Speight, T. M., Avery, G. S. 1982. Domperidone: a review. Drugs 24:360-400
82. Agid, Y., Quinn, N., Lhermitte, F. 1981. Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone. Rev. Neurol. 137:49-51
83. Stefanini, E., Clement-Cormier, Y. 1981. Detection of dopamine receptors in the area postrema. Eur. J. Pharmacol. 74:257-60
84. Reid, J. L., Greenacre, J. K., Teychenne, P. F. 1976. Cardiovascular actions of L-dopa and dopaminergic agonists in parkinsonism. In Advances in Parkinsonism, ed. W. Birkmayer, O. Hornykiewicz, pp. 566-72. Basel: Roche
85. Shindler, J. S., Finnerty, G. T., Towlson, K., Dolan, A. L., Davies, C. L., Parkes, J. D. 1984. Domperidone and levodopa in Parkinson's disease. Br. J. Clin. Pharmacol. 18:959-62
86. Quinn, N., Illas, A., Lhermitte, F., Agid, Y. 1981. Bromocriptine in Parkinson's disease: a study of cardiovascular effects. J. Neurol. Neurosurg. Psych. 44:426-29
87. Baldessarini, R. J., Frankenburg, F. R. 1991. Clozapine: a novel antipsychotic agent. N. Engl. J. Med. 324:746-54
88. Meltzer, H. Y., Gudelsky, G. A. 1992. Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile. Arznelmittelforschung 42:268-72
89. Kahn, N., Freeman, A., Juncos, J. L., Manning, D., Watts, R. L. 1991. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 41: 1699-1700
90. Pakkenberg, H., Pakkenberg, B. 1986. Clozapine in the treatment of tremor. Acta Neurol. Scand. 73:295-97
91. Friedman, J. H., Lannon, M. C. 1990. Clozapine-responsive tremor in Parkinson's disease. Mov. Disord. 5: 225-29
92. Fischer, P. A., Baas, H., Hefner, R. 1990. Treatment of parkinsonian tremor with clozapine. J. Neural Transm. Park. Dis. Dement. Sect. 2:233-38
93. Kopin, I. J. 1992. Features of the dopaminergic neurotoxin MPTP. Ann. NY Acad. Sci. 648:96-104
94. Singer, T. P., Ramsay, R. R. 1990. Mechanism of the neurotoxicity of MPTP. An update. FEBS Lett. 274:1-8
95. Tanner, C. M., Langston, J. F. 1990. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 40(3):17-31
96. Parker, W. D. Jr., Boyson, S. J., Parks, J. K. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:719-23
97. Yoshino, H., Nakagawa-Hattori, Y., Kondo, T., Mizuno, Y. 1992. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 4(1):27-34
98. Bindoff, L. A., Birch-Machin, M. A., Cartlidge, N. E., Parker, W. D. Jr., Turnbull, D. M. 1991. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J. Neurol. Sci. 104(2):203-8
99. Shoffner, J. M., Watts, R. L., Juncos, J. L., Tononi, A., Wallace, D. C. 1991. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol. 30:332-39
100. Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., Marsden, C. D. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:823-27
101. Mann, V. M., Cooper, J. M., Krige, D., Daniel, S. E., Schapira, A. H., Marsden, C. D. 1992. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115:333-42
102. Golbe, L. I. 1991. The genetics of Parkinson's disease: a reconsideration. Neurology 40(3):7-14
103. +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170:1049-55
104. Di Monte, D. A, Wu, E. Y., Delanney, L. E., Irwin, I., Langston, J. W. 1992. Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. J. Pharmacol. Exp. Ther. 261:44-49
105. Cleeter, M. W., Cooper, J. M., Schapira, A. H. 1992. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58:786-89
106. Jenner, P. 1991. Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. 136:6-15 (Suppl.)
107. Saggu, H., Cooksey, J., Dexter, D., Wells, F. R., Lees, A., et al. 1989. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 153:692-97
108. Perry, T. L., Yong, V. W. 1986. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67:269-74
109. Ambani, L. M., Van Woert, M. H., Murphy, S. 1975. Brain peroxidase and catalase in Parkinson's disease. Arch. Neurol. 32:114-18
110. Floyd, R. A., Zaleska, M., Harmon, H. J. 1984. Possible involvement of iron in oxygen free radicals in aspects of aging in brain. In Free Radicals in Molecular Biology: Aging and Disease, ed. D. Armstrong, R. S. Sohal, R. G. Cutler, T. F. Slater, pp. 143-61. New York: Raven
111. Spina, M. B., Cohen, G. 1989. Dopamine turnover and glutathione oxidation. Implications for Parkinson's disease. Proc. Natl. Acad. Sci. USA 86:1398-1400
112. Cohen, G., Spina, M. B. 1989. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 26:689-90
113. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., et al. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52(2):381-89
114. Halliwell, B., Gutteridge, J. M. C. 1984. Oxygen toxicity, oxygen radicals, transition metals and disease. J. Biochem. 219(1):1-14
115. Graham, D. G. 1984. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 5:83-95
116. Sofic, E., Paulus, W., Jellinger, K., Riederer, P., Youdim, M. B. 1991. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 156: 978-82
117. Hirsch, E. C., Brandel, J. P., Gaile, P., Javoy-Agid, F., Agid, Y. 1991. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56:446-51
118. Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., Youdim, M. B. 1990. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 2:327-40
119. Dexter, D. T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F. R., et al. 1991. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1114:1953-75
120. Ben-Shachar, D., Riederer, P., Youdim, M. B. 1991. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57:1609-14
121. Johnston, J. P. 1968. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Psychopharmacol. 17(7):1285-97
122. Knoll, J., Magyar, K. 1972. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5:393-408
123. Hunter, K. R., Boakes, A. J., Laurence, D. R., Stern, G. M. 1970. Monoamine oxidase inhibitors and L-dopa. Br. Med. J. 3:388
124. Elsworth, J. D., Glover, V., Reynolds, G. P., et al. 1978. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the "cheese effect." Psychopharmacology (Berlin) 57:33-38
125. Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W. 1975. Potentiation of antikinetic effect after L-dopa treatment by an inhibitor of MAO-B, L-deprenyl. J. Neural Transm. 36:303-23
126. Glover, V., Sandler, M., Owen, F., Riley, G. J. 1977. Dopamine is a monoamine oxidase B substrate in man. Nature 265:80-81
127. Birkmayer, W., Knoll, J., Riederer, P., Youdim, M. B., Hars, V., Marton, J. 1985. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson's disease: a longterm study. J. Neural Transm. 654(2):113-27
128. Tetrud, J. W., Langston, J. W. 1989. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 41:519-22
129. The Parkinson Study Group. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321:1364-71